
Developing antibody-drug conjugates for effective treatment of T cell cancers.


coremsg

Anti-TRBC1 antibody–drug conjugates may offer a more potent T cell&nbsp;cancer therapy by bypassing the fratricide that may be limiting the efficacy of&nbsp;anti-TRBC1 CAR T cells in the&nbsp;clinical trial for patients with T cell cancers.

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers - Nature

developing-antibody-drug-conjugates-for-t-cell-cancers


Developing Antibody-Drug Conjugates for T Cell Cancers
